-
1 month ago | 
medcitynews.com | Frank Vinluan |Michael Blackman |Eve McDavid
AbbVie is joining the chase for new obesity drugs, but rather than getting a me-too GLP-1 drug, the pharmaceutical giant is landing rights to a clinical-stage molecule that goes after two novel targets to trigger weight loss. Under deal terms announced Monday, AbbVie will pay Danish company Gubra $350 million up front for rights to its drug, GUB014295. AbbVie will lead further clinical development as well as commercialization.
-
1 month ago | 
medcitynews.com | Marissa Plescia |Eve McDavid |Michael Blackman
This roundup is meant to highlight some of the most notable funding rounds of the month and is not intended to be comprehensive. Health tech companies made several major funding announcements in February. Here is a list of some of the biggest funding rounds. OpenEvidence secures $75 million in Series A fundingOpenEvidence is a company that aims to expand the world’s medical knowledge. It offers an AI copilot for doctors that helps them make medical decisions at the point of care.
-
1 month ago | 
medcitynews.com | KEVIN WANG |Eve McDavid
While companies like Walmart and Walgreens once had stars in their eyes and believed they could “fix” healthcare, last year we saw retail giants rapidly jumping ship from the primary care business after investing billions and concluding that “healthcare isn’t a sustainable business model.” Retail healthcare might be convenient, but a meaningful primary care experience can’t be replicated in a store.
-
1 month ago | 
medcitynews.com | Marissa Plescia |Eve McDavid
Tia, a women’s health company, is partnering with food-as-medicine platform Nourish to offer women food and nutrition support, the companies announced Thursday. San Francisco-based Tia offers in-person and virtual support for women. Its services include gynecology, primary care, mental health and wellness support.
-
1 month ago | 
medcitynews.com | Marissa Plescia |Eve McDavid |Stephanie Baum
On the campaign trail, President Donald Trump declared himself the “father of IVF” and announced that the government or insurance companies should pay for it. IVF (in vitro fertilization) is a medical procedure in which an egg is fertilized by sperm outside the body. It is used by couples who are unable to get pregnant naturally.
-
1 month ago | 
medcitynews.com | Frank Vinluan |Stephanie Baum |Eve McDavid
Zevra Therapeutics is still ramping up sales of its new FDA-approved drug, but the company has already found a way to cash in big on this therapy for a rare metabolic disorder. The priority review voucher awarded alongside the approval of Miplyffa will be sold for $150 million, Zevra announced Thursday. The buyer of the voucher was not disclosed. Celebration, Florida-based Zevra said it expects the transaction will close within 30 to 45 days.
-
1 month ago | 
medcitynews.com | Stephanie Baum |Eve McDavid
MedCity INVEST 2025, scheduled for May 20-21 in Chicago at the Willis Tower, is a boutique healthcare investor event spotlighting healthcare innovation trends as well as healthcare and life science startups. Jenni Le, a principal and investor withVenture Investors Health Fund, is a judge for the medtech track of the Pitch Perfect contest. In response to emailed questions, Le shared her thoughts on entrepreneur and investor role models. To view the agenda for INVEST click here.
-
1 month ago | 
medcitynews.com | Katie Adams |Eve McDavid |Stephanie Baum
Healthcare CFOs expect minimal financial gains in 2025, as high labor costs and insufficient payer rates continue to be major obstacles, according to survey data released last week by financial software company Strata Decision Technology. The data is based on survey responses from more than 100 finance professionals working at healthcare provider organizations.
-
1 month ago | 
medcitynews.com | Frank Vinluan |Eve McDavid
Eikon Therapeutics, a company headed by the former Merck executive who steered the cancer drug Keytruda to FDA approval, has raised $350.7 million to support a pipeline that includes a lead drug candidate now in a pivotal test that could support expanding melanoma treatment to a pair of new immunotherapy targets. The lead Eikon drug, EIK1001, is a small molecule designed to hit toll-like receptors 7 and 8 (TLR7/8).
-
1 month ago | 
medcitynews.com | Adam Mendelsohn |Eve McDavid
For patients managing chronic conditions, medication adherence plays a crucial role in successful treatment. However, adherence rates are alarmingly low, with only about 50% of patients consistently following prescribed regimens. This lack of adherence contributes to the estimated $500 billion in avoidable healthcare costs and 125,000 preventable deaths annually in the United States.
